The value of inhaled drugs has been recognised for millenia by ancient
civilizations (Miller, 1973). Inhalation therapy has many advantages
including drug delivery direct to site of action, rapid onset of therapeutic
effect (Plit et aI, 1972) minimisation of dose required (Newman &
Clarke, 1985) minimisation of systemic side-effects (Sterling, 1978),
avoidance of first pass metabolism (C & D Livingstone, 1988) and noninvasive
delivery technique. However, specific drug delivery may be
hindered by defence mechanisms of the respiratory tract (Reiser &
Warner, 1986), and other problems may also be present since drug
delivery depends on the mechanism of deposition (Newman, 1984),
particle size (Rees et aI, 1982), inhalation mode (Pavia et aI, 1977) and
patient factors. The types of drugs used in inhalation therapy include
the beta adrenergic stimulants, anticholinergic bronchodilators,
methylxanthines, sodium cromoglycate, corticosteroids, water and saline
aerosols, mucolytics and antibiotics. The delivery systems employed are
the nebuliser, dry powder inhalers and the metered dose inhalers
(MDls). Recently, a new device has been developed, and this is the
Turbohaler.peer-reviewe